Reported 2 days ago
CVS Health Corporation (NYSE:CVS) showed significant gains in the first quarter of 2025, with a 15.72% increase in stock value over the past year and a revenue of $94.59 billion, marking a 7% year-over-year growth. The investor letter from PGIM Jennison Health Sciences Fund highlighted CVS's leading market positions in health insurance, pharmacy, and drug benefits, noting that improvements in management and performance could boost earnings significantly in the coming years. However, while CVS shows promise, the article suggests that AI stocks may offer greater investment potential.
Source: YAHOO